Enovis Q1 Sales Rise 5% to $589M with Adjusted EBITDA of $104M
Enovis reported Q1 net sales of $589 million, up 5% reported and 3% organic year-over-year, with reconstructive sales rising 11% reported. The company posted adjusted EBITDA of $104 million and $0.89 adjusted EPS while reaffirming full-year 2026 guidance of $2.31-2.37 billion revenue and $425-435 million EBITDA.
1. First-Quarter Financial Results
Enovis reported net sales of $589 million, up 5% reported and 3% organic, with a net loss of $8 million, or 1.4% of sales. Adjusted EBITDA reached $104 million, or 17.6% of sales, and adjusted EPS was $0.89.
2. Segment Performance
Reconstructive sales grew 11% on a reported basis and 6% organically, driven by recent product launches. Performance & Rehabilitation (P&R) segment was flat reported and rose 1% organically, reflecting stable end markets.
3. 2026 Financial Outlook
Enovis reaffirmed full-year guidance for 2026, forecasting revenue of $2.31-2.37 billion (4-6% organic growth), adjusted EBITDA of $425-435 million, adjusted EPS of $3.52-3.73, and free cash flow conversion of 25% or higher.
4. Strategic Priorities
Management highlighted commercial execution, innovation in product introductions, operational excellence and financial discipline as key to navigating near-term uncertainties and driving long-term growth.